NIKKEI 225
39,038.16 +354.23 (+0.92%) HANG SENG
18,366.95 -109.85 (-0.59%) CRUDE OIL
77.87 +2.34 (+3.10%) GOLD FUTURES
2,329.00 +4.00 (+0.17%) DOW
38,836.29 +37.30 (+0.10%) Bitcoin GBP
54,620.01 -135.24 (-0.25%)
NBIX Dec 2024 105.000 call
| Previous close | 35.70 |
| Open | 17.90 |
| Bid | 34.20 |
| Ask | 38.70 |
| Strike | 105.00 |
| Expiry date | 2024-12-20 |
| Day's range | 17.90 - 35.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 301 |
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In addition, Neurocrine Biosciences prese
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal. The CAHtalyst Pediatric Phase 3 study met the primary and key secondary endpoints related to androgen reduction (duri
PR NewswireNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal. The study met the primary and important key secondary endpoints related to androgen reduction (du
